David Apelian is Interim CEO of Eiger BioPharmaceuticals Inc.
Person profile
Latest filings (excl ownership)
No filings
Latest ownership filings
4
Eiger BioPharmaceuticals, Inc.
6 Jul 23
4
Eiger BioPharmaceuticals, Inc.
2 Feb 23
4
Eiger BioPharmaceuticals, Inc.
18 Aug 22
4
Eiger BioPharmaceuticals, Inc.
11 Mar 22
4
Eiger BioPharmaceuticals, Inc.
15 Mar 21
4
Eiger BioPharmaceuticals, Inc.
13 Mar 20
4
Eiger BioPharmaceuticals, Inc.
26 Mar 19
4
Eiger BioPharmaceuticals, Inc.
16 Mar 18
4
Eiger BioPharmaceuticals, Inc.
9 Jan 18
4
Eiger BioPharmaceuticals, Inc.
6 Oct 17
Recent insider trades
Date | Company | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 23 | EIGR Eiger BioPharmaceuticals | Stock Option Common Stock | Grant | Acquire A | No | No | 1.65 | 170,000 | 280.50 k | 170,000 |